Dainippon Sumitomo Pharma Co., Ltd. ("DSP") (Headquarters: Osaka, Japan) and Takeda Pharmaceutical Company Limited ("Takeda") (Headquarters: Osaka, Japan) today announced that the European Medicines Agency (EMA) has confirmed the acceptance for review of the Marketing Authorization Application (MAA) for an atypical antipsychotic medication lurasidone hydrochloride for the treatment of schizophrenia. The MAA was filed by Takeda Global Research & Development Centre (Europe). Lurasidone, orally
CP Foods Captures Four Awards at Thailand Marketing Award 2024
—
Charoen Pokphand Foods Public Company Limited (CP Foods) has earned four distinguished aw...
Thai Students Triumph at International Brand Planning Marketing Awards
—
A six-member student team from Thailand has won the prestigious Champion English ...
Xinhua Silk Road: Orah mandarins in Guangxi's Xingbin District poised to enter overseas markets
—
During the 20th China-ASEAN Expo, orah mandarins from Xi...
Marketing Association of Thailand Recommends Businesses to Adjust Plans to Cope with 4 Marketing Trends
—
Marketing Association of Thailand Recommends Bus...
Dataxet Touts MarTech Platforms at CTC2023, Enhancing Marketing Efficiency for Business Sector
—
Dataxet Limited (dataxet:infoquest) underscored its posit...
Bidmath wins multiple awards from the 2022 Marketing Excellence Awards
—
Bidmath was announced the SILVER winner in Excellence in Personalisation Marketin...
SYS Introduces the H-BEAM "Green Steel Series", Thailand's First Eco-Friendly Steel, to lead the Green Ecosystem Trend in the Green Construction Industry
—
Siam Yamato...